logo
LucyRx and Personify Health Join Forces to Tackle Rising Employer GLP-1 Costs with Proven, Member-Centered Solutions

LucyRx and Personify Health Join Forces to Tackle Rising Employer GLP-1 Costs with Proven, Member-Centered Solutions

Yahoo11-06-2025
The combined offering provides employers with a proven approach to GLP-1s, including managing costs, supporting member wellbeing, and reducing long-term health risks
BETHESDA, Md. & PROVIDENCE, R.I., June 11, 2025--(BUSINESS WIRE)--LucyRx, an independent, next-generation pharmacy benefits manager (PBM), and Personify Health®, the company making healthier easier, today announced a strategic partnership to offer employers a more personalized, clinically grounded approach to GLP-1 medication management and weight care.
Through the partnership, LucyRx and Personify Health will deliver an integrated solution that combines pharmacy benefit strategy with personalized support from GLP-1-trained coaches, individualized care plans for medication management, and education from Personify's Transform Weight Management solution. This holistic program provides members with tailored, coach-led guidance, encouragement and resources to effectively manage their weight and medication.
Together, the two companies are helping employers navigate the rising demand and cost of GLP-1 medications with a model that prioritizes member success and long-term cost management for employers. The partnership is especially impactful for health systems and mission-driven employers, where clinical quality and financial accountability go hand in hand.
The new LucyRx/Personify Health joint effort builds on the success employers are already experiencing using LucyRx for GLP-1 management. For example, an 11,000 life employer group has recorded:
An average weight loss per member of 22 pounds in 12 weeks.
40% improvement in medication adherence.
$3.2 million in total health care savings.
90% member-reported satisfaction and improved well-being.
"Employers have an incredible opportunity to reduce long-term health care costs through successful weight management programs like ours," said David Blair, CEO of LucyRx. "Partnering with Personify Health allows us to deliver precisely what employers and their members need to be successful and ultimately healthier, which is our primary goal. This collaboration reflects our belief that smarter pharmacy benefits should always prioritize the people we serve."
Key elements of the joint GLP-1 strategy include:
Targeted prior authorization standards designed to ensure therapy reaches those who will benefit most.
Real-time clinical reviews and benefit optimization powered by LucyIQ™, LucyRx's proprietary AI platform.
Personalized support from certified health coaches from Personify Health.
Menopause-specific care pathways and behavioral health support from LucyRx.
Structured step-down protocols to optimize long-term outcomes.
"Roughly 9% of the U.S. population is predicted to become GLP-1 users by 2030 – that's 30 million people. The growing need for chronic condition support and increasing expectations for employer-sponsored GLP-1 benefits offerings have driven employers to rethink their approach," said Jeffrey Jacques, MD, chief medical officer at Personify Health. "Together with LucyRx, we are providing members with meaningful wrap-around support that gives them the tools and education they need for long-lasting, healthy lifestyles – whether using a weight management medication or not."
About LucyRx
LucyRx is an independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide.
This is prescription care, brilliantly reimagined.
Learn more at LucyRx.com.
About Personify Health
Personify Health empowers diverse and unique businesses – and diverse and unique people – to engage more deeply in health at a lower cost. By bringing modern third party administration, holistic wellbeing, and navigation solutions together, all in one place, we have created the industry's first and only personalized health platform. With global operations and decades of experience (formerly Virgin Pulse and HealthComp), the company engages and empowers people to live healthier lives. Through our proprietary combination of data-driven personalization, science-backed methodology, and concierge-level clinical expertise, our end-to-end platform makes it easier to proactively address people's chronic care to everyday needs. With a personalized, engaging, and powerfully simple experience, we are redefining industry expectations and what it means to manage health. Learn more at www.personifyhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611132722/en/
Contacts
LucyRx Media Contact Tricia Bancroft516-241-6157press@lucyrx.com
Personify Health Media Contact Julie Sculleyjulie.sculley@personifyhealth.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Agriculture Imaging Sensor Market Size, Share, Trends, Analysis, and Forecast 2025-2034
Agriculture Imaging Sensor Market Size, Share, Trends, Analysis, and Forecast 2025-2034

Associated Press

time32 minutes ago

  • Associated Press

Agriculture Imaging Sensor Market Size, Share, Trends, Analysis, and Forecast 2025-2034

DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Agriculture Imaging Sensor Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges' has been added to offering. The global agriculture imaging sensor market is projected to reach a value of USD 6.4 billion by 2034, growing at a CAGR of 15.7% from USD 1.7 billion in 2025. This research aids top management, strategists, business developers, sales managers, and investors by offering global and regional market sales data, insights on market trends, competitive analysis through SWOT, and financial projections to navigate and invest strategically in the agriculture imaging sensor market. This growth reflects the increasing demand for advanced monitoring solutions in precision agriculture. Imaging sensors like multispectral, hyperspectral, and thermal sensors capture high-resolution imagery and crucial data, providing insights into crop health, soil conditions, and environmental factors. These technologies enhance farmers' ability to detect diseases, pests, and nutrient deficiencies, optimize irrigation systems, and ultimately improve crop yields. As agriculture becomes more data-driven, imaging sensors' role in this technological evolution is set to expand significantly. The market is currently witnessing notable advancements in sensor technology. Multispectral and hyperspectral sensors' increasing precision allows farmers to gather more detailed data on plant health and soil conditions. These sensors are increasingly integrated with drones, UAVs, and satellite systems to facilitate large-scale monitoring, improving efficiency and coverage. The proliferation of IoT-based systems further enhances real-time data collection and analysis capabilities. Additionally, incorporating AI and machine learning with sensor data is yielding actionable insights, empowering farmers with data for informed decision-making regarding crop management and resource allocation. Looking towards 2025 and beyond, the market anticipates further innovation in sensor miniaturization and affordability, extending these technologies' accessibility to small-scale farmers. Integration with AI-powered analytics platforms paves the way for predictive analytics that will enable anticipation of crop needs and environmental changes. The focus on sustainable and climate-resilient agriculture is rising, prompting demand for advanced imaging sensors to monitor environmental variables and improve resource efficiency. With the increasing adoption of smart farming practices, imaging sensors will become even more critical in optimizing operations and boosting yields. Key Market Trends: Market Drivers: Market Challenges: Market Segmentation: Key Attributes: Companies Featured For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: TECHNOLOGY PHOTOGRAPHY AGRICULTURE NATURAL RESOURCES SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 07:11 AM/DISC: 07/03/2025 07:11 AM

Shift4 Completes Acquisition of Global Blue
Shift4 Completes Acquisition of Global Blue

Business Wire

time35 minutes ago

  • Business Wire

Shift4 Completes Acquisition of Global Blue

CENTER VALLEY, Pa. & SIGNY, Switzerland--(BUSINESS WIRE)--Shift4 Payments, Inc. ('Shift4') (NYSE: FOUR), the leader in integrated payments and commerce technology, and Global Blue Group Holding AG ('Global Blue') (NYSE: GB), the leading specialty payments and technology platform enabling tax-free shopping, dynamic currency conversion, and payments solutions to the world's largest retail brands, today announced the successful completion of the tender offer by GT Holding 1 GmbH, an indirect wholly owned subsidiary of Shift4, to purchase the outstanding shares of Global Blue (the 'Shares') for $7.50 per common share in cash (the 'Tender Offer'). 'This marks the largest acquisition in Shift4's history and reinforces our track record of bold moves that expand our capabilities and deliver the most comprehensive commerce offering in the industry,' said Shift4 CEO Taylor Lauber. 'By integrating Global Blue into our end-to-end platform, we're further expanding our global reach and solidifying our position as a leading unified commerce provider that adds meaningful value to our merchants around the world.' With over 40 years of history, Global Blue is a market leader at the intersection of travel and luxury retail across Europe, Asia, and South America. Hundreds of thousands of premium retail and hospitality locations rely on Global Blue's tax-refund and currency conversion technology, including the world's most iconic luxury and premium retailers as well as other large retail electronics, sportswear and fast fashion brands. Global Blue is the market share leader in the tax-free shopping category, a service that is essential for retailers and other merchants catering to international travelers. Global Blue's merchant solutions will be added to Shift4's global payments platform to deliver an enhanced end-to-end experience for its merchants. The addition of tax refund and currency conversion capabilities enhances Shift4's position as an innovative vendor and trusted partner. Global Blue is the most comprehensive two-sided network in its category, connecting millions of affluent international shoppers to its merchants and directly engaging with international shoppers through its proprietary app, creating powerful network effects and allowing for further product innovation, such as loyalty, digital marketing, and more. Now that the acquisition has closed, Shift4 and Global Blue will soon plan to launch an all-in-one payment terminal to provide VAT refund, DCC, and payment processing services to global merchants. The combined company will be the only provider in the market delivering a complete solution for merchants that combines these three services in a single device. As a result of the transaction, Ant International and Tencent will become strategic partners with Shift4. The partnership will explore collaboration on global e-commerce payment products, including the distribution of global e-wallet gateway service Alipay+, which connects global merchants with 1.7 billion user accounts of 36 digital payment methods across the world, and WeChat Pay, the most widely used mobile payment service in China, throughout the Shift4 ecosystem. The Tender Offer expired as scheduled at one minute after 11:59 p.m. (New York City time) on July 2, 2025. Equiniti Trust Company, LLC, the depositary and paying agent for the Tender Offer, has advised Shift4 and Global Blue that as of the expiration of the Tender Offer, 233,862,778 Shares had been validly tendered and not properly withdrawn pursuant to the Tender Offer, representing in the aggregate approximately 97.37% of the issued and outstanding Shares. All of the conditions to the consummation of the Tender Offer have been satisfied, and Shift4 has accepted for payment and will promptly pay for all Shares that have been validly tendered and not properly withdrawn in accordance with the terms of the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission (the 'SEC') on March 21, 2025, as amended. Effective immediately following the completion of the Tender Offer, the current directors of Global Blue were replaced with those Shift4 appointed directors as approved by the Global Blue shareholders at the extraordinary general meeting of shareholders held on May 6, 2025. As previously announced, Shift4 intends to cause Global Blue to delist its shares from NYSE and effect a squeeze-out merger under Swiss law to acquire all remaining 2.63% of outstanding Shares. About Shift4 Shift4 (NYSE: FOUR) is boldly redefining commerce by simplifying complex payments ecosystems across the world. As the leader in commerce-enabling technology, Shift4 powers billions of transactions annually for hundreds of thousands of businesses in virtually every industry. For more information, visit About Global Blue Global Blue (NYSE: GB) is the business partner for the shopping journey, providing technology and services to enhance the experience and drive performance. With over 40 years of expertise, today we connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across 52 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Each of Shift4 and Global Blue intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Shift4's or Global Blue's, as applicable, respective expectations associated with the acquisition of Global Blue by Shift4, including the completion of the squeeze-out merger, the benefits, synergies, efficiencies, and opportunities arising from the acquisition, and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause each of our actual results, performance or achievements, respectively, to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the substantial and increasingly intense competition worldwide in the financial services, payments and payment technology industries; each of our ability to continue to expand our respective share of the existing payment processing markets or expand into new markets; additional risks associated with each of our expansion into international operations, including compliance with and changes in foreign governmental policies, as well as exposure to foreign exchange rates; and each of our respective ability to integrate and interoperate each of our services and products with a variety of operating systems, software, devices, and web browsers, and the other important factors discussed under the caption 'Risk Factors' in Part I, Item 1A in Shift4's Annual Report on Form 10-K for the years ended December 31, 2023 and December 31, 2024, under the caption 'Key Items – Risk Factors' in Item 3(D) in Global Blue's Annual Report on Form 20-F for the years ended March 31, 2025 and March 31, 2024 and each of our other filings with the SEC, respectively. Any such forward-looking statements represent management's expectations as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, each of Shift4 and Global Blue, disclaim any obligation to do so, even if subsequent events cause each of our views to change, respectively.

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

timean hour ago

  • Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company's common stock to one new employee (the 'Inducement Grant') on July 1, 2025 (the 'Grant Date'). The Inducement Grant has been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the 'Plan') but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to the individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of Viridian's common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to the employee's continued employment with Viridian through the applicable vesting dates. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store